Septerna (NASDAQ:SEPN) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen downgraded shares of Septerna (NASDAQ:SEPN) from a strong-buy rating to a buy rating in a report published on Saturday morning.

SEPN has been the subject of a number of other reports. HC Wainwright upped their target price on shares of Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. Raymond James Financial assumed coverage on Septerna in a report on Friday, December 19th. They issued a “strong-buy” rating and a $38.00 target price on the stock. Jones Trading began coverage on Septerna in a report on Tuesday, December 23rd. They set a “buy” rating and a $43.00 price target for the company. Truist Financial initiated coverage on Septerna in a research note on Monday, December 15th. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, Wells Fargo & Company upgraded Septerna from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $18.00 to $28.00 in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $33.00.

Septerna Stock Performance

Septerna stock opened at $25.30 on Friday. Septerna has a one year low of $4.17 and a one year high of $30.50. The stock has a fifty day moving average of $25.39 and a 200 day moving average of $18.74. The stock has a market cap of $1.13 billion, a PE ratio of -16.75 and a beta of 3.85.

Septerna (NASDAQ:SEPN) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.19 by ($0.28). Septerna had a negative net margin of 266.77% and a negative return on equity of 17.98%. The firm had revenue of $21.50 million for the quarter, compared to the consensus estimate of $24.50 million. As a group, sell-side analysts predict that Septerna will post -7.11 EPS for the current fiscal year.

Insider Activity

In related news, SVP Daniel D. Long sold 3,501 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $18.06, for a total transaction of $63,228.06. Following the completion of the sale, the senior vice president owned 92,911 shares in the company, valued at approximately $1,677,972.66. This trade represents a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 4.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Covestor Ltd raised its position in shares of Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock valued at $68,000 after buying an additional 1,296 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Septerna by 15.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after acquiring an additional 1,315 shares during the last quarter. PharVision Advisers LLC increased its holdings in Septerna by 17.5% in the 3rd quarter. PharVision Advisers LLC now owns 11,932 shares of the company’s stock valued at $224,000 after acquiring an additional 1,780 shares during the last quarter. Russell Investments Group Ltd. purchased a new stake in Septerna in the 3rd quarter worth $36,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Septerna by 88.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after purchasing an additional 1,945 shares during the last quarter.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.